A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia
Condition(s):Early Stage Breast CancerLast Updated:September 6, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Early Stage Breast CancerLast Updated:September 6, 2019Completed
Condition(s):Fever, Sweats, and Hot Flashes; Neutropenia; Unspecified Childhood Solid Tumor, Protocol SpecificLast Updated:February 14, 2014Completed
Condition(s):Patient Preference; Febrile Neutropenia, Drug-Induced; Patient SatisfactionLast Updated:March 15, 2024Active, not recruiting
Condition(s):Chemotherapy-induced Neutropenia; Febrile Neutropenia, Drug-Induced; Epithelial Ovarian Cancer; Colony Stimulating Factors Adverse Reaction; Granulocyte Colony Stimulating Factor; Cost-effectiveness Analysis; Quality of Life; Progression-free Survival; Overall SurvivalLast Updated:October 8, 2019Unknown status
Condition(s):Febrile NeutropeniaLast Updated:August 15, 2023Completed
Condition(s):Febrile Neutropenia, Drug-InducedLast Updated:December 15, 2023Terminated
Condition(s):Acute Myeloid LeukemiaLast Updated:March 28, 2022Unknown status
Condition(s):Gynecologic Cancer; Myelosuppression Adult; Febrile Neutropenia; Chemotherapy-induced NeutropeniaLast Updated:January 7, 2019Unknown status
Condition(s):Pediatric Cancer; Febrile Neutropenia; Chemotherapy-induced Neutropenia; OncologyLast Updated:July 8, 2021Completed
Condition(s):Pediatric Cancer; Febrile Neutropenia; Oncology; Chemotherapy-induced NeutropeniaLast Updated:July 11, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.